Tarek Mouhieddine, MD, discusses the predictive role of ferritin levels and ALC in patients with multiple myeloma receiving bispecific antibodies.
Tarek H. Mouhieddine, MD
Advertisement
Articles by Tarek H. Mouhieddine, MD
Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
SERENA-6 Meets PFS2 End Point With Early Switch to Camizestrant in ER+/HER2-Negative, ESR1-Mutated Advanced Breast Cancer
5